The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The Duffy antigen/receptor for chemokines (DARC) is a promiscuous chemokine receptor that binds to members of the CXC chemokine family possessing angiogenic properties. The DARC is expressed on erythrocytes and endothelial cells and is required for Plasmodium vivax infection of erythrocytes. Approximately 70% of African‐Americans lack erythrocyte expression of the DARC as a genetic mechanism of protection against malaria infection. African‐American men have a 60% greater incidence of prostate cancer and a 2‐fold higher mortality rate than Caucasian men. Using a transgenic model of prostate cancer with DARC‐deficient mice, we tested the hypothesis that lack of DARC expression on erythrocytes contributes to enhanced prostate tumor growth. In vitro, erythrocytes from wild‐type mice but not DARC‐deficient mice cleared angiogenic chemokines produced by prostate cancer cells and reduced endothelial cell chemotaxis. In vivo, tumors from DARC‐deficient mice had higher intra‐tumor concentrations of angiogenic chemokines, increased tumor vessel density, and greatly augmented prostate tumor growth. The data suggest that the DARC functions to clear angiogenic CXC chemokines from the prostate tumor microcirculation and that the lack of erythroid DARC, as occurs in the majority of African‐Americans, may be a contributing factor to the increased mortality to prostate cancer in this popula‐tion.—Shen, H., Schuster, R., Stringer, K. F., Waltz, S. E., Lentsch, A. B. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J. 20, 59–64 (2006)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis
Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27348 · Cited by 1,222 · cited 2×
“Site-directed mutagenesis studies have shown that the ELR motif confers angiogenic properties to CXC chemokines, primarily via endothelial cell chemotaxis (6, 7).”
BackgroundMethodTournamille, C., Colin, Y., Cartron, J. P., & Le Van Kim, C. (1995) · Nature Genetics · doi:10.1038/ng0695-224 · Cited by 741 · cited 2×
“We propose that the greater mortality to prostate cancer in men of African descent is due in part to the genetic mutation that prevents expression of the DARC on erythrocytes that evolved long ago as a natural selection against malaria infection ( 15 ).”
Background
Cited by
Chemokines and the immune response to cancer
Ozga, A. J., Chow, M. T., & Luster, A. D. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.012 · Cited by 830
Chemokines and chemokine receptors: new insights into cancer-related inflammation
Lazennec, G., & Richmond, A. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.003 · Cited by 650
The role of CXC chemokines and their receptors in cancer
Vandercappellen, J., Van Damme, J., & Struyf, S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.050 · Cited by 643
Role of chemokines in tumor growth
Raman, D., Baugher, P. J., Thu, Y. M., & Richmond, A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.05.013 · Cited by 578
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
Mollica Poeta, V., Massara, M., Capucetti, A., & Bonecchi, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00379 · Cited by 583
Metadata
- Authors
- Shen, H., Schuster, R., Stringer, K. F., Waltz, S. E., & Lentsch, A. B.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 20
- Issue
- 1
- Pages
- 59-64
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2073435945
- Cited by
- 139
- References
- 2
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.